Sales and Marketing

Vectura investors ignore critics and back tobacco giant takeover

Tobacco giant Philip Morris International (PMI) has won the shareholder vote it needed for its controversial £1.1 billion takeover of respiratory drugmaker Vectura, despite mobilised opposition to the deal. PMI said it had won support from enough shareholders that – when added to its own holding in Vectura – it had a 75% position in …

Vectura investors ignore critics and back tobacco giant takeover Read More »

EFPIA: Partnership is the key to healthcare’s biggest challenges

The European pharma body’s new Health Collaboration Guide hopes to inspire greater partnership working across healthcare, showcasing award-winning collaborations involving Pfizer, Janssen, Novartis and more. Partnership is the key to unlocking the solutions to our major healthcare challenges, and “no player has a monopoly on good ideas”. That’s according to the European Federation of Pharmaceutical …

EFPIA: Partnership is the key to healthcare’s biggest challenges Read More »

EU ‘negotiating with Valneva’ over COVID-19 vaccine contract

The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to supply COVID-19 vaccines that was terminated by the UK government this week. A French government source told Reuters that the EU is considering using the VLA2001 vaccine as part of its booster campaign plans, along with a …

EU ‘negotiating with Valneva’ over COVID-19 vaccine contract Read More »

Valneva slumps as UK dumps €1.4bn order for COVID-19 jab

The UK has terminated its order for up to 190 million doses of a COVID-19 vaccine developed by French biotech company Valneva, accusing it of breaching their supply agreement. Valneva said it “strenuously denies” that allegation, but added that the €1.4 billion ($1.65 billion) contract does provide the UK government with the right to exit …

Valneva slumps as UK dumps €1.4bn order for COVID-19 jab Read More »

Biogen admits slow Aduhelm launch, as scientists question label again

Shares in Biogen have come under pressure after chief executive Michel Vounatsos admitted that the company is facing a much slower than anticipated rollout of its controversial Alzheimer’s disease therapy Aduhelm. Speaking at a Morgan Stanley conference yesterday, Vounatsos said Biogen may have to revisit its sales forecasts for Aduhelm (aducanumab), which were already “very …

Biogen admits slow Aduhelm launch, as scientists question label again Read More »

Preparing for a post-pandemic world

Janssen’s Mark Hicken, VP of strategy, EMEA, looks at what COVID-19 has taught us and how we can become stronger as we emerge from the pandemic. There’s plenty of talk about a post-COVID world right now, which can seem strange when so many places are still feeling the impact or remain in the grip of …

Preparing for a post-pandemic world Read More »

Sanofi snaps up Kadmon and its transplant drug Rezurock

Less than a month after Kadmon Pharma launched its first product – Rezurock for a complication of organ transplants – the New York company has agreed to be bought by Sanofi in a $1.9 billion deal. The merger agreement, which has been agreed by the boards of both companies, will see Sanofi pay $9.50 per …

Sanofi snaps up Kadmon and its transplant drug Rezurock Read More »

Mallinckrodt moves closer to resolving its opioid liability hangover

Mallinckrodt looks like it could join Purdue Pharma in reaching a settlement in its bankruptcy proceedings related to opioid litigation, after years of legal wrangling. The Ireland-headquartered drugmaker filed for bankruptcy last year, after proposing a $1.6 billion payout to settle lawsuits claiming that its marketing of opioid painkillers helped to fuel an epidemic in …

Mallinckrodt moves closer to resolving its opioid liability hangover Read More »

EU, AstraZeneca reach resolution in COVID-19 supply spat

AstraZeneca’s legal dispute with the European Commission over a shortfall in the supply of COVID-19 vaccines promised by the company earlier this year has been settled in advance of court proceedings. Under the terms, AZ has agreed to deliver 60 million doses of its Vaxzevria vaccine to the EU by the end of this month, …

EU, AstraZeneca reach resolution in COVID-19 supply spat Read More »

Purdue bankruptcy court hands immunity to Sackler family

A US federal judge has approved a bankruptcy settlement for Purdue Pharma that grants the Sackler family that owned the business immunity from any further civil lawsuits accusing them of contributing to opioid epidemic – to the consternation of campaigners. The agreement will dissolve the OxyContin (oxycodone) manufacturer – which Judge Robert Drain said was …

Purdue bankruptcy court hands immunity to Sackler family Read More »

FDA clears J&J’s twice-yearly Invega for schizophrenia

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Janssen is trumpeting a new version of its Invega drug that could solve that problem. The FDA has just approved Janssen’s Invega Hafyera (paliperidone), a twice-yearly injectable formulation that extends the company’s big-selling brand and offers the …

FDA clears J&J’s twice-yearly Invega for schizophrenia Read More »

Galapagos’ long-serving CEO Onno van de Stolpe to retire

After 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership. He will stay in his role until a successor is found, according to the company, which has kicked off a search for a new CEO. …

Galapagos’ long-serving CEO Onno van de Stolpe to retire Read More »

Nine ways to keep focus and boost your pharma career

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. His second column addresses the vital importance of prioritisation. There used to be times when every single task seemed important. Naturally. I’m a perfectionist …

Nine ways to keep focus and boost your pharma career Read More »

Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case

Gilead Sciences’ Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol-Myers Squibb over patents relating to CAR-T therapies, overturning a $1.2 billion fine levied last year. In December 2019, a jury found that Kite infringed on a patent owned by Juno Therapeutics, a division of BMS acquired through its …

Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case Read More »

Vertex’s Nicola Massey: the pharmaphorum podcast

In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager in the UK and Ireland. Having joined the biopharmaceutical company only fairly recently, they discuss her career path to Vertex, and also what it was like to join virtually – something that’s Increasingly common for many people …

Vertex’s Nicola Massey: the pharmaphorum podcast Read More »

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis’ copycat drug Byooviz. Byooviz (ranibizumab, also known as SB11) has been cleared for the same indications as Lucentis – including namely wet age-related macular degeneration (AMD) and diabetic macular oedema (DMO – and will …

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz Read More »

Organon Makes Women’s Health a Priority

Simon Nicholson tells us how Organon, a new women’s healthcare company, is working to effect positive change globally by listening to women about their health care needs and allowing that information to drive their business development strategy. As Merck looked to expand its portfolio, it was determined that there’s a huge problem and need, particularly …

Organon Makes Women’s Health a Priority Read More »

Alex Gorsky will pass leadership of J&J to Joaquin Duato in January

Johnson & Johnson has appointed Joaquin Duato as chief executive officer to replace long-serving Alex Gorsky, who has been CEO since 2012. Joaquin Duato Gorsky will stay on at the company as executive chairman, but Duato – currently vice chairman at J&J’s executive committee – will take the top job at the company on 3 …

Alex Gorsky will pass leadership of J&J to Joaquin Duato in January Read More »

Years after Pfizer merger, ex-Medivation exec gets insider trading charge

A Medivation executive at the heart of the company’s team that sold the company to Pfizer for $14 billion five years ago is facing allegations of insider trading. Matthew Panuwat A complaint filed by the US Securities and Exchange Commission (SEC) today accuses Matthew Panuwat, the then-head of business development at Medivation, of buying sizeable …

Years after Pfizer merger, ex-Medivation exec gets insider trading charge Read More »

Novartis says trials back Beovu safety in diabetic eye disease

There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the big question facing the company is whether it is less safe. Data from phase 3 trials of the drug in diabetic macular oedema (DMO) provide some encouragement for Novartis on …

Novartis says trials back Beovu safety in diabetic eye disease Read More »

Novartis says trials back Beovu safety in diabetic eye disease

There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the big question facing the company is whether it is less safe. Data from phase 3 trials of the drug in diabetic macular oedema (DMO) provide some encouragement for Novartis on …

Novartis says trials back Beovu safety in diabetic eye disease Read More »

As the smoke clears, Vectura backs tobacco giant PMI’s bid

Vectura’s board has decided to recommend a takeover bid from tobacco giant Philip Morris International, despite being urged by health charities to go for a lower offer from investment company Carlyle Group. A just-published statement from the respiratory drug specialist said that its directors concluded that PMI’s 165p per share offer – which values the …

As the smoke clears, Vectura backs tobacco giant PMI’s bid Read More »

UK cues up more Pfizer/BioNTech vaccines as price row looms

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. A report in The Times claims that the government is paying £22 a dose – up from an earlier price of £18 …

UK cues up more Pfizer/BioNTech vaccines as price row looms Read More »

Carlyle baulks at Vectura auction, but urges shareholders to back its bid

Private equity group Carlyle has said it won’t raise its offer for respiratory drug specialist Vectura to match a 165p per share offer from tobacco giant Philip Morris International (PMI). The investment firm said its 155p offer was “full and fair” and would not be raised, meaning that it would not enter into a head-to-head …

Carlyle baulks at Vectura auction, but urges shareholders to back its bid Read More »

Gene therapy specialist bluebird exits “untenable” European market

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. On the firm’s second-quarter results call, Obenshain said the biotech will start “an orderly wind-down” …

Gene therapy specialist bluebird exits “untenable” European market Read More »

Dental implant market: Top trends bolstering industry growth

People across the world, especially the population aged 65 years or older, are suffering from some form of a medical condition that results in tooth decay or loss. According to statistics released by the Centers for Disease Control and Prevention, around 70.1% of the population in North America was 65 years or more and was …

Dental implant market: Top trends bolstering industry growth Read More »

AZ gets European approvals for Forxiga in chronic kidney disease

AstraZeneca’s Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with chronic kidney disease, extending its lead over rival drugs in the class. The European Commission has cleared Forxiga (dapagliflozin) for CKD in adults with or without diabetes, and the drug becomes the first new drug treatment for …

AZ gets European approvals for Forxiga in chronic kidney disease Read More »

Bidding war breaks out for respiratory specialist Vectura

A flurry of new offers by Philip Morris International (PMI) and private equity firm Carlyle has hiked the value of respiratory medicines company Vectura to £1 more than a billion ($1.4 billion), with the tobacco giant leading the bidding at the latest count. Carlyle first broke ground with a 136 pence per share offer that …

Bidding war breaks out for respiratory specialist Vectura Read More »

Moderna COVID-19 jab sales rocket to $4.2 billion in second quarter

Moderna made a massive $4.2 billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. The tally makes the SpikeVax (mRNA-1273) vaccine the second biggest seller behind Pfizer/BioNTech’s Comirnaty, which pulled in $7.8 billion in the second quarter and …

Moderna COVID-19 jab sales rocket to $4.2 billion in second quarter Read More »

Pfizer, Flynn in the firing line again over UK epilepsy drug pricing

The UK’s Competition and Markets Authority (CMA) has resurrected a complaint against Pfizer and Flynn Pharma, claiming the two companies charged the NHS excessive prices for a widely-used epilepsy therapy. In a provisional judgment, the CMA has concluded that Pfizer and Flynn abused a dominant position to overcharge the NHS for phenytoin sodium capsules, causing …

Pfizer, Flynn in the firing line again over UK epilepsy drug pricing Read More »

FTC drops AbbVie antitrust case, but fires a parting shot at the firm

AbbVie will not be pursued any further by the US government over allegations that it used ‘sham’ litigation to keep competition to its AndroGel testosterone replacement product off the market. The Federal Trade Commission (FTC) sad it had dropped its antitrust complaint against the company after the US Supreme Court declined to review a lower …

FTC drops AbbVie antitrust case, but fires a parting shot at the firm Read More »

UK fines Advanz £100m for raising thyroid drug price tenfold

The UK has levied another big fine for anticompetitive activity in the pharma market in a fortnight, with Advanz Pharma and former owners on the hook for more than £100 million ($140 million) after increasing the price of a thyroid disease drug by 1,110% over an eight-year period. The Competition and Markets Authority (CMA) said …

UK fines Advanz £100m for raising thyroid drug price tenfold Read More »

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but making it available at no profit had weighed on its profit margins. R&D expenses leaped 28% in the period, an increase that AZ said was “primarily” a result of its …

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss Read More »

Pfizer hikes COVID vaccine sales forecast for 2021 to $33.5bn

Continuing orders for Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty have prompted near one-third increase in its projected revenues for the vaccine this year, from $26 billion to $33.5 billion. It’s a big increase, considering the former figure was the drugmaker’s best guess just three months ago, and takes into account additional supply agreement signed from mid-April …

Pfizer hikes COVID vaccine sales forecast for 2021 to $33.5bn Read More »

Martin Shkreli’s $7.4m forfeit is paid, thanks to that Wu-Tang Clan album

The US government has sold off the one-of-a-kind Wu-Tang Clan album famously bought by ‘pharma bro’ Martin Shkreli, with the proceeds enough to wipe out his $7.4 million fine for defrauding investors. Shkreli, the pharma entrepreneur who became notorious in 2015 for hiking the price of a lifesaving drug, bought the Once Upon a Time …

Martin Shkreli’s $7.4m forfeit is paid, thanks to that Wu-Tang Clan album Read More »

Martin Shkreli’s $7.4m forfeit is paid, thanks to that Wu-Tang Clan album

The US government has sold off the one-of-a-kind Wu-Tang Clan album famously bought by ‘pharma bro’ Martin Shkreli, with the proceeds enough to wipe out his $7.4 million fine for defrauding investors. Shkreli, the pharma entrepreneur who became notorious in 2015 for hiking the price of a lifesaving drug, bought the Once Upon a Time …

Martin Shkreli’s $7.4m forfeit is paid, thanks to that Wu-Tang Clan album Read More »

Syneos Health appoints Michael Brooks as Chief Development Officer

Syneos Health has appointed Michael Brooks as its new chief development officer. In this newly created role, Brooks will lead the company’s customer engagement and market development portfolio. “COVID-19 has forever changed the way we work with customers and colleagues, and how we effectively engage with patients and health care providers. It’s more important than …

Syneos Health appoints Michael Brooks as Chief Development Officer Read More »

GSK names McNamara as CEO of consumer health spinout

GlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer – will retain the top job at the business after it is hived off into a separate company next year. The appointment, which had been expected, was confirmed in a statement by GSK’s board today. McNamara has …

GSK names McNamara as CEO of consumer health spinout Read More »

Biogen bites back at critics of Aduhelm after drug’s slow start

Biogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting the company to issue a rebuke to what it says is “extensive misinformation and misunderstanding” about the drug. In an open letter, R&D chief Al Sandrock tackled a number of the criticisms levelled at the FDA’s decision …

Biogen bites back at critics of Aduhelm after drug’s slow start Read More »

Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readout

Phase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of last year, but the company is already in discussions with the FDA about a route to approval. There has been speculation since the unexpected approval of Biogen and Eisai’s Aduhelm (aducanumab) last month that other amyloid therapies …

Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readout Read More »

Ten tips on pharma time management

Oliver Stohlmann’s new Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. In this first instalment he tackles managing time. A month into exiting my career of over two decades in global life-science multinationals, I’m …

Ten tips on pharma time management Read More »

Is J&J nearing the end of its opioid liability hangover?

Johnson & Johnson and the ‘big three’ US pharma wholesalers are on the brink of a $26 billion settlement deal covering thousands of lawsuits alleging their involvement in contributing to the US opioid crisis, according to press reports. Under the deal, J&J would be in line for a $5 billion payment over nine years, while …

Is J&J nearing the end of its opioid liability hangover? Read More »

Healthware Group appoints Giovanni Loria as chief financial officer

Giovanni Loria has joined global digital health innovation organisation Healthware Group as its new chief financial officer. He will be responsible for the overall financial management and will play a pivotal role in driving long-term business and strategic growth, supporting the company in its future evolution. Loria said: “I am delighted to join the Healthware …

Healthware Group appoints Giovanni Loria as chief financial officer Read More »

UK comms agency Fishawack Health restructures creative team

Fishawack Health has announced a restructuring of its creative team to expand client support across global markets. The Fishawack creative team is led by Lacey Jae Christman and Damien Parsonage and includes 12 creative directors with a breadth of experience. It includes talent from award-winning agencies — Carling Communications, rare-disease specialty agency Dudnyk, 2e Creative, …

UK comms agency Fishawack Health restructures creative team Read More »

UK fines drugmakers record £260m for price gouging NHS

The UK’s competition authority has issued its largest ever fine of more than £260 million ($360 million) to several pharma companies accused of colluding to hike the price of medicines delivered to the NHS. The Competition and Markets Authority (CMA) took the action against Auden Mckenzie and Actavis UK – now known as Accord-UK – …

UK fines drugmakers record £260m for price gouging NHS Read More »

Why pharma needs a revolution in culture

James Dempsey breaks down the misconception that culture can’t be measured, and gives tips for how companies can implement a clear culture strategy. In 2014, six years after the global financial crisis forced the world’s biggest financial institutions into some serious navel gazing, the CEO of a major international bank was despairing: “We’ve put in …

Why pharma needs a revolution in culture Read More »

Final hurdle falls as UK backs AZ’s $39bn takeover of Alexion

The UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a broader inquiry into the deal. The nod from the Competition and Markets Authority (CMA) after an initial assessment means that it concluded no antitrust risks were associated with the deal. It was the final needed from a …

Final hurdle falls as UK backs AZ’s $39bn takeover of Alexion Read More »

Big tobacco’s PMI makes another pharma foray with Vectura deal

Tobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector, following up its recent acquisition of Fertin Pharma with a deal to buy Vectura for around £1 billion ($1.38 billion). PMI is paying 150 pence per share for Vectura, trumping a 139 per share offer from private equity firm …

Big tobacco’s PMI makes another pharma foray with Vectura deal Read More »

Another hurdle down as EU clears AstraZeneca’s Alexion takeover

The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across the line. The EU approval comes after the merger has already been okayed by the US, Japan and a number of other countries around the world, …

Another hurdle down as EU clears AstraZeneca’s Alexion takeover Read More »

Nestle gets closer to Seres, pledging $525m for microbiome C. diff drug

Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for Clostridium difficile infections. Under the terms of the new deal, Nestle’s Health Sciences unit will pay Seres another $125 million if the FDA approves the drug …

Nestle gets closer to Seres, pledging $525m for microbiome C. diff drug Read More »

Elliott fires broadside at GSK in wake of investor update

GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at an investor meeting last week would deflect criticism of her leadership from activist investor Elliott Management – but finds herself in the firing line once again today. The US hedge fund, run by billionaire Paul Singer, has …

Elliott fires broadside at GSK in wake of investor update Read More »

Elliott fires broadside at GSK in wake of investor update

GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at an investor meeting last week would deflect criticism of her leadership from activist investor Elliott Management – but finds herself in the firing line once again today. The US hedge fund, run by billionaire Paul Singer, has …

Elliott fires broadside at GSK in wake of investor update Read More »

EU and AZ both claim victory in COVID jab supply lawsuit

A court in Belgium has ordered AstraZeneca to deliver additional doses of its COVID-19 vaccine to EU member states by 27 September, although far fewer than the amount sought by the European Commission. The EU had requested 120 million doses by the end of this month and 300 million by end-September, but the judge in …

EU and AZ both claim victory in COVID jab supply lawsuit Read More »

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn, explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying that if pharmaceutical companies are not profitable, they will not survive. The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are …

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities Read More »

Merck nabs $1.2 billion order for oral COVID antiviral from US

The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for use by the FDA. The $1.2 billion deal is among the largest placed by the federal government for a COVID-19 medicine, reflecting molnupiravir’s potential as an orally-active …

Merck nabs $1.2 billion order for oral COVID antiviral from US Read More »

FDA clears Pfizer’s Prevnar 20 for adults, as Merck rival nears decision

Pfizer has the FDA approval it was seeking for Prevnar 20, the latest update to its blockbuster pneumococcal vaccination franchise, keeping it one step ahead of a competing shot from Merck & Co. The US regulator has cleared the pneumococcal conjugate vaccine – which protects against 20 common strains of Streptococcus pneumoniae – for adults …

FDA clears Pfizer’s Prevnar 20 for adults, as Merck rival nears decision Read More »

Dermavant raises $200m to ease launch of Otezla rival tapinarof

Dermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches the market, and it has just cut a deal to defray those costs. The Roivant group company has raised $160 million from investors plus a $40 million credit facility that it can draw on if – and …

Dermavant raises $200m to ease launch of Otezla rival tapinarof Read More »

Experts discuss the field force’s customer-centric future

The ways in which HCPs prefer to engage with pharma has been changing for quite some time, and the digital transformation brought by COVID has dramatically accelerated that. In a recent pharmaphorum webinar, in partnership with Axtria, commercialisation experts from across the industry discussed how the right field force training and execution in combination with …

Experts discuss the field force’s customer-centric future Read More »

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicines.  Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation – which will be sold as Wegovy – …

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy Read More »

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicines.  Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation – which will be sold as Wegovy – …

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy Read More »

PM Society Training: Essentials of Pharmaceutical Marketing

Who will benefit? New and aspiring marketers and those wanting to refresh their marketing thinking and be fitter to handle today’s healthcare environment. Topics covered Overview of pharmaceutical marketing Pharmaceutical marketing strategy concepts and tools Effective market and competitor analysis Increasing impact through effective segmentation & targeting Building competitive advantage through creative product positioning The …

PM Society Training: Essentials of Pharmaceutical Marketing Read More »

Moderna ramps up EU COVID jab capacity via Lonza deal

Capacity to supply Moderna’s COVID-19 vaccine in Europe could be swelled by round 300 million doses a year, following an agreement to set up a new production line at contract manufacturer Lonza. The increased capacity depends on Moderna getting approval for a half dose of an updated version of the mRNA-1273 vaccine – targeting new …

Moderna ramps up EU COVID jab capacity via Lonza deal Read More »

Novartis halts three trials of Beovu eye drug on safety concerns

Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD). On the plus side, Beovu (brolucizumab) met its efficacy objectives in the MERLIN study, but that was offset by higher rates of inflammatory reactions in the eyes …

Novartis halts three trials of Beovu eye drug on safety concerns Read More »

Ashfield Engage acquires US consulting firm Nuvera LLC

Ashfield Engage has completed the acquisition of Nuvera, a US-based healthcare consulting firm specialising in patient support programmes. Ashfield Engage and Nuvera will offer integrated specialist support and services including late-phase clinical trial experience, implementation and post-commercialisation satisfaction benchmarking and service optimisation. Nareda Mills, global president, patient solutions, Ashfield Engage said the combined expertise of …

Ashfield Engage acquires US consulting firm Nuvera LLC Read More »

Pharma’s post-COVID prospects: the pharmaphorum podcast

In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season. Meade talked about the prospects for the industry as the UK and other economies beginning to recover from the devastating pandemic. He discussed how COVID vaccines have …

Pharma’s post-COVID prospects: the pharmaphorum podcast Read More »

FDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clash

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with uterine fibroids.  The drug will be sold as Myfembree (relugolix) for the uterine fibroids indication, and is already available to treat prostate cancer under …

FDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clash Read More »

EU asks court to fine AstraZeneca over missing COVID jab shipments

Lawyers for the European Commission asked a court in Brussels today to fine AstraZeneca millions of euros for its “obvious”  failure to meet the terms of its contract to supply COVID-19 vaccines to the EU. Rafael Jafferali Counsel for the Commission – Rafael Jafferali – insisted during the hearing at the Brussels Court of First …

EU asks court to fine AstraZeneca over missing COVID jab shipments Read More »

Vectura agrees $1.4bn takeover by private equity group Carlyle

Vectura has agreed to a £1.55 per share takeover by US private investment company Carlyle, which values the UK drug delivery specialist at £958 million ($1.4 billion).  The acquisition of one of the UK’s biggest biotech companies comes as Vectura is in the midst of a business restructuring that has seen it pivot away from …

Vectura agrees $1.4bn takeover by private equity group Carlyle Read More »

How diversity can help life sciences advance its lifesaving solutions

Paula Parfitt discusses the importance of workplace diversity and how life science companies can build a thriving, diverse workforce. Diversity, equity and inclusion (D, E & I) is a sensible business choice with significant commercial benefits. A homogenous workforce has a smaller pool of collective experience, meaning that when problems arise, collective creativity and innovation …

How diversity can help life sciences advance its lifesaving solutions Read More »

COVID jab rollout provides short opportunity for pharma to build trust

After decades of struggling with poor public perception, the pharma industry has an opportunity to generate stronger connections with consumers than ever thanks to the COVID-19 vaccine drive – but it will have to move quickly.  That is the conclusion of a Mediahub study which cites recent poll data in the US giving the industry …

COVID jab rollout provides short opportunity for pharma to build trust Read More »

UK competition watchdog probes AstraZeneca, Alexion merger

The antitrust authority in the UK has launched an investigation into the proposed $39 billion takeover of US firm Alexion by AstraZeneca. The Competition and Markets Authority (CMA) is starting the first phase of the probe today, and said it should wrap it up by 21 July, deciding at that point whether to start a …

UK competition watchdog probes AstraZeneca, Alexion merger Read More »

What is modular content and why do pharma marketers need it NOW?

Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more content and creating personalised content to meet the demands of their customers. It is a newer concept for pharma marketers, however, who are now turning to modular solutions in response …

What is modular content and why do pharma marketers need it NOW? Read More »

Key insights for a successful first-time product launch

Pre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of big pharma. But with the proper planning and an agile approach, they can be more successful than they realise, says Veeva’s Ian Hale. He takes us through the challenges of a successful launch and explains what pre-commercial …

Key insights for a successful first-time product launch Read More »

Designing HCP engagement for the next normal

Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck. Restrictions to in-person face-to-face interactions have resulted in increased use of remote and digital channels. Many life sciences companies have begun 2021 by reviewing how they respond to the longer-term impact of this change, and its …

Designing HCP engagement for the next normal Read More »

WebMD buys clinical best practice information firm MGP

WebMD Health Corp, a health information services company, has announced it has acquired MGP, an information provider supporting clinical best practice and implementation of best practice guidelines.  In a statement WebMD said the acquisition combines the core competencies of MGP with that of Medscape, WebMD’s flagship global brand for healthcare professionals. Medscape and its affiliate …

WebMD buys clinical best practice information firm MGP Read More »

Sian Hurst promoted to MD of Clark Health Communications

Sian Hurst has been promoted to managing director of independent UK-based healthcare comms agency, Clark Health Communications.  In a statement the company said Hurst joined the agency in June 2020 and made an immediate impact across the business, doubling the agency’s pitch win rate and helping to diversify the client base, while mentoring the growing …

Sian Hurst promoted to MD of Clark Health Communications Read More »

4 ways to embed data-driven best practice in pharma HCP communications

Virtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever for pharma companies to maintain up-to-date customer data. Over the 12 months to December 2020 the number of global Veeva CRM Engage Meetings increased sixfold, while those held in Europe saw an eight-fold increase – with 200,000 remote …

4 ways to embed data-driven best practice in pharma HCP communications Read More »

AS&K Group makes twin hire with Zdinak and Facco

The AS&K Group has made two appointments, hiring Alana Zdinak as its new sales and marketing director, while Chiara Facco joins its agency brand Remedica as account director.  AS&K said Zdinak (pictured right) brings with her over 25 years’ experience in the healthcare communications and education industry. In a statement it noted that she has …

AS&K Group makes twin hire with Zdinak and Facco Read More »

Bobbitt promoted to strategy director role at The Bloc

Antoinette Bobbitt has been promoted to executive vice president, strategy director at independent US creative agency, The Bloc. As EVP, Strategy Director, Antoinette will be responsible for ensuring that the agency’s talent, planning methodology, and tools are aligned with the Bloc’s vision of building exceptional customer experiences. She will oversee the strategy for several clients, …

Bobbitt promoted to strategy director role at The Bloc Read More »

performance-io adds Jason McKenna as a non-executive director

UK-based performance-io has added to its senior team through two promotions and the appointment of STEM Healthcare CEO Jason McKenna as a non-executive director. He will oversee the online performance marketing and digital benchmarking agency’s growth in the US joins Rob Wood and Barrie Brien on performance-io’s non-executive board. McKenna has been with STEM since …

performance-io adds Jason McKenna as a non-executive director Read More »

Novo Nordisk ups forecasts after Q1 profit boost

After an indifferent period Novo Nordisk has kicked off 2021 on the front foot, raising its financial forecast after posting better than expected Q1 earnings and sales. The world’s biggest manufacturer of diabetes drugs expects growth in constant currencies at between 6% and 10%, up from the previous forecast in the 5%-9% range. Operating profit …

Novo Nordisk ups forecasts after Q1 profit boost Read More »

Pfizer says COVID-19 jab could rake in $26bn this year

Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world’s biggest-selling medicines.  The company also said that it doesn’t expect the massive sales to be a one-off, as demand from governments around the world for coronavirus vaccines will continue to be …

Pfizer says COVID-19 jab could rake in $26bn this year Read More »

Langland appoints Mike Brightley as advertising creative director

Langland has appointed Mike Brightley as creative director for its advertising section. Brightley has more than 14 years of healthcare advertising experience and has worked for companies including Ogilvy Healthworld, PAN and was most recently associate creative director at TBWA/WorldHealth. Brightley has worked on several insightful campaigns including applied emotion-recognition technology for adaptive storytelling. He …

Langland appoints Mike Brightley as advertising creative director Read More »

Dentsu launches global healthcare agency dentsu health

Dentsu International has announced the launch of a global healthcare agency dentsu health. The New York-based marketing firm said the new venture will draw upon the expertise of dentsu’s global network of 2,000 health marketing experts across 85 markets in EMEA, APAC and the Americas. The agency will provide a single point of contact now …

Dentsu launches global healthcare agency dentsu health Read More »

Merck looks at M&A deals as COVID hits sales in Q1

Ken Frazier’s final appearance on Merck & Co’s financial results call as chief executive was a muted affair, as the company reported lower-than-expected revenues dragged down as the pandemic continued to restrict patient access to healthcare.  Pharmaceutical sales were flat on the same period of 2020 at $10.7 billion, with vaccines sales falling nearly 19% …

Merck looks at M&A deals as COVID hits sales in Q1 Read More »

Healthware appoints Yannick Valenti to senior digital role in the UK

Healthware Group has appointed Yannick Valenti as digital strategy and customer engagement director out of its UK office. He moves to the global consultancy and digital health company from Ogilvy Health, where he spent three years as digital strategy director. Prior to that Valenti was the European general manager for digital advertising company SRAX, focusing on …

Healthware appoints Yannick Valenti to senior digital role in the UK Read More »

Healthware appoints Yannick Valenti to senior digital role in the UK

Healthware Group has appointed Yannick Valenti as digital strategy and customer engagement director out of its UK office. He moves to the global consultancy and digital health company from Ogilvy Health, where he spent three years as digital strategy director. Prior to that Valenti was the European general manager for digital advertising company SRAX, focusing on …

Healthware appoints Yannick Valenti to senior digital role in the UK Read More »

Indigo Medical merges with imc group

Indigo Medical, a provider of material review, medical signatory approval services and medical communication for global pharmaceutical and biopharma companies, is joining imc group with the backing of pan-European investor Waterland Private Equity. In a statement the companies said the merger will help imc provide a one-stop service for clients across seven core divisions: Medical …

Indigo Medical merges with imc group Read More »

What comes next: digital transformation in B2B life sciences sales

As the contours of a post-pandemic world begin to take shape, those working B2B sales in the life sciences acknowledge that the industry must adapt to some permanent shifts. Mert Yentur looks at what is next for the industry. Even prior to COVID-19, sales teams reckoned with traditional online-only CRM systems that didn’t align well …

What comes next: digital transformation in B2B life sciences sales Read More »

Prime Global appoints Emma Sutcliffe as SVP Patient Insights and Solutions

Prime Global, the international medical communications and market access group, has appointed Emma Sutcliffe as senior vice president, patient insights and solutions. Sutcliffe will lead on patient engagement and support Prime Global’s seven agencies and four consultancies to deliver patient-centric communications. She has a strong heritage in patient engagement strategy, HCP and patient education, and …

Prime Global appoints Emma Sutcliffe as SVP Patient Insights and Solutions Read More »

EU orders another 100m doses of Pfizer/BioNTech COVID jab

The EU has continued a refocus of its COVID-19 vaccination drive on mRNA shots, ordering another 100 million doses of Pfizer and BioNTech’s Comirnaty shot.  The new deal takes the total number of Comirnaty shots ordered by the EU for delivery this year to 600 million, and comes amid an ongoing debate about the safety …

EU orders another 100m doses of Pfizer/BioNTech COVID jab Read More »

Fernandez and Loveya take senior roles at FCB Health

Consumer advertising guru Humberto Fernandez has joined FCB Health as group creative director, with Anna Loveya joining the company’s market access healthcare agency Mosaic Group as management director. Fernandez comes to FCB Health New York following 25 years in consumer advertising, during which he’s delivered creative solutions to several blockbuster brands, including Coca-Cola, Bayer, Kit …

Fernandez and Loveya take senior roles at FCB Health Read More »

Fishawack buys health economics consultancy PRMA

UK comms agency Fishawack Health has acquired the health economics outcomes research (HEOR) consultancy PRMA Consulting. PRMA has offices across Europe, Asia and the US and adds expertise in Asia-Pacific and European markets to the company’s market access offering in North America. The company said that the acquisition will allow it to offer a HEOR …

Fishawack buys health economics consultancy PRMA Read More »

AZ exits US vaccine plant after mix-up spoils J&J’s COVID jab

AstraZeneca is shifting production of its COVID-19 vaccine away from a plant in Baltimore which also makes Johnson & Johnson’s shot, after human error resulted in the contamination of 15 million doses.  The mix-up at the facility operated by contract manufacturer Emergent BioSolutions resulted in ingredients destined for AZ’s AZD1222 jab being mixed into vials …

AZ exits US vaccine plant after mix-up spoils J&J’s COVID jab Read More »

What Is The Best Way to Incentivise a Digital-First Sales Team?

Incentivising people with KPI-linked bonuses is nothing new. Especially in commercial roles it has long been standard. The issue with KPIs is they can be very ineffective. If clearly defined they will get you results, but if not, they can just reinforce the wrong behaviours. The difficulty is to define the right ones. Bottomline is …

What Is The Best Way to Incentivise a Digital-First Sales Team? Read More »

Country focus: Hungary carves out a niche in digital pharma

AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO and co-founder, Szabolcs Nagy, to find out why moving beyond traditional biotech drug development is a good fit for the country’s ecosystem. Hungarian company, Turbine, is taking an alternative approach …

Country focus: Hungary carves out a niche in digital pharma Read More »

Precision Value & Health acquires Across Health

Pharma marketing specialist Precision Value & Health has acquired the specialist communications consultancy Across Health. Across Health is a leading global omnichannel engagement consultancy focused on providing clients an analytical and evidence-based framework for commercial strategy, execution, and resource optimisation. The company’s solutions are based around its proprietary Navigator365 product suite, which more than 40 …

Precision Value & Health acquires Across Health Read More »

J+D Forecasting provides Online Team Pharma Forecasting Training

Following the success of J+D’s face to face training, the content has been redesigned to make it suitable for an online audience. The training can be tailored to individual teams/departments within specific organisations or completed independently. There is a significant need for an improved approach to pharmaceutical forecasting. Improved model design, enhanced usability, efficient processes …

J+D Forecasting provides Online Team Pharma Forecasting Training Read More »

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

Alexion’s senior vice president of its international business talks to Paul Tunnah about the importance of “people-centred and vulnerable” leadership, the surprising impacts of COVID and the promising future for treating patients with rare diseases.  Alexion is a somewhat unique pharma company in that it focuses almost entirely on rare diseases – and although this …

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease Read More »

VMLY&Rx appoints Nichole Davies as global chief strategy officer

VMLY&Rx, a comms agency dedicated to prescription pharmaceutical companies who are researching and developing breakthrough therapies, has hired Nichole Davies as global chief strategy officer.  Davies will lead a new global strategic practice to deliver and enable connected health strategies for clients. The team comprises specialists across a wide range of strategic expertise including brand, …

VMLY&Rx appoints Nichole Davies as global chief strategy officer Read More »

Envision acquire dDOC, hires Manish Goel as tech solutions head

Comms company Envision Pharma Group has acquired doDOC Corp, a document collaborative review, editing and authoring firm. doDOC enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today. While …

Envision acquire dDOC, hires Manish Goel as tech solutions head Read More »

Red Havas launches ‘global health micro-network’

Red Havas has announced the launch of Red Havas Health, a global micro-network focused on health, in response to increasing demand from clients globally. The new offering brings together health professionals from Red Havas across the US, Australia, Singapore, Vietnam and the Philippines, as well as Havas Health PR in New York, Havas Life Medicom PR based …

Red Havas launches ‘global health micro-network’ Read More »

Red Havas launches ‘global health micro-network’

Red Havas has announced the launch of Red Havas Health, a global micro-network focused on health, in response to increasing demand from clients globally. The new offering brings together health professionals from Red Havas across the US, Australia, Singapore, Vietnam and the Philippines, as well as Havas Health PR in New York, Havas Life Medicom PR based …

Red Havas launches ‘global health micro-network’ Read More »

Havas Lynx Group reigns at PM Society Awards 2021

Havas Lynx Group were the big winners of the 35th annual PM Society Awards on Thursday 18 March, picking up six Gold awards, five Silver and three Bronze awards. Over 1000 people tuned in online to watch the virtual awards ceremony which was hosted by PM Society Chairs Caroline Benson and Colin Williams and head …

Havas Lynx Group reigns at PM Society Awards 2021 Read More »

Havas Lynx Group reigns at PM Society Awards 2021

Havas Lynx Group were the big winners of the 35th annual PM Society Awards on Thursday 18 March, picking up six Gold awards, five Silver and three Bronze awards. Over 1000 people tuned in online to watch the virtual awards ceremony which was hosted by PM Society Chairs Caroline Benson and Colin Williams and head …

Havas Lynx Group reigns at PM Society Awards 2021 Read More »

Roche expands COVID testing portfolio with $1.8bn GenMark deal

Roche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic capabilities and adding rapid COVID tests to its pandemic arsenal.  GenMark’s tests are designed to rapidly detect multiple pathogens from a single patient sample. Of particular interest at the moment are its Respiratory Pathogen Panels, which identify …

Roche expands COVID testing portfolio with $1.8bn GenMark deal Read More »

Amar Urhekar joins Ashfield Health as global president

Former McCann Health veteran Amar Urhekar has joined Ashfield Health network as global president. Following a healthcare communications career spanning over two decades of leadership in five countries, Amar Urhekar takes the helm as global president of the more than 1,450-strong network that has rebranded from Ashfield Healthcare Communications to Ashfield Health. Since joining, Urhekar …

Amar Urhekar joins Ashfield Health as global president Read More »

Lucid Group eyes global expansion with new ICG investment

The Lucid Group has secured new investment from Intermediate Capital Group (ICG) to support its ambitions to be a global business. The healthcare communications group, which already has offices in the UK, US and Asia and currently employs around 250 people, said the deal would support further expansion across geographies – particularly in the US, …

Lucid Group eyes global expansion with new ICG investment Read More »

Pharma poised to cash in on ‘long COVID’ symptoms

While there’s hope that vaccination campaigns may bring the pandemic under control, “long COVID” side effects may continue to affect patients for some time. According to analysts from Jefferies, several pharma companies could stand to benefit with products that could help with issues such as mental health, lung scarring, kidney disease and heart failure. Although …

Pharma poised to cash in on ‘long COVID’ symptoms Read More »

Why pharma isn’t yet achieving digital excellence, and how it can get there

Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. COVID has seen pharma sales experience three years’ worth of digital transformation in …

Why pharma isn’t yet achieving digital excellence, and how it can get there Read More »

Guide provides best practice tips on approaching health journalists

The UK’s Healthcare Communications Association (HCA) and Medical Journalists’ Association have launched a new best practice guide on approaching health journalists with a media story. Based on research by the Medical Journalists’ Association and feedback from their members, the guide aims to help all those working in healthcare PR understand how best to approach journalists …

Guide provides best practice tips on approaching health journalists Read More »

Syneos adds to European team with key hires

Syneos Health Communications has made several senior hires to strengthen its Europe-based team. A portfolio of Syneos Health agencies, Syneos Health Communications, offers expertise spanning advertising and branding, public relations and medical communications. Orrin Pollard Among the most notable hires is Orrin Pollard, who joins as director of European creative expression. Pollard has more than …

Syneos adds to European team with key hires Read More »

McCann Health promotes Dan Carucci to global chief medical officer

McCann Health has announced the promotion of medical director Dan Carucci to global chief medical officer.  An expert voice in the scientific and medical community, Dr Carucci will use vast knowledge and experience in innovative medicine, practice and delivery to contribute authoritative science to the agency’s clients and businesses. In this new role, Carucci will …

McCann Health promotes Dan Carucci to global chief medical officer Read More »

Tribal Health appoints Niaz Rizwani as strategy director

Tribal Health has appointed Niaz Rizwani as strategy director, joining from Publicis Health where he was a senior strategist. Rizwani will support Tribal Health’s clients across multiple activities, connecting a client’s commercial goals with interactive customer experiences, shaping data strategies and omnichannel planning, knowledge sharing, and delivering innovative approaches. Launched last year, Tribal Health is …

Tribal Health appoints Niaz Rizwani as strategy director Read More »

A history of Johnson & Johnson

By most measures the single largest pharma company in the world, US-based Johnson & Johnson (J&J) is also arguably one of the most well-known drugmakers among the general public.  Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical …

A history of Johnson & Johnson Read More »

Tribunal maintains Lexon’s £1.2m fine for breaking competition law

Pharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused it of exchanging commercially sensitive information about prices for nortriptyline tablets.  Lexon had appealed against a ruling by the UK’s Competition and Markets Authority (CMA) that it had exchanged information with King Pharmaceuticals and Alissa Healthcare Research …

Tribunal maintains Lexon’s £1.2m fine for breaking competition law Read More »

Diana Evans joins Makara as director during hiring spree

UK-based international healthcare communications agency Makara Health has appointed 11 additional people to its rapidly growing team, including Diana Evans who joins the leadership team as director. Evans comes with both agency and in-house experience, including her latest role at Napp Pharmaceuticals as head of communications. Diana will spearhead Makara’s patient engagement offering. Other additions …

Diana Evans joins Makara as director during hiring spree Read More »

Onyx Health targets digital growth with new executive director

Healthcare marketing communication specialists Onyx Health has marked a year of continued growth and expansion with Trevor Pill’s appointment as executive director. The new role is a significant promotion for Pill, who originally joined the agency as a client campaign manager. He then rose through the ranks to become associate director, working on a strategic …

Onyx Health targets digital growth with new executive director Read More »

Reality Check | Is Your Current Customer Engagement Solution the Best Choice for All Markets?

Do your sales reps drive a Ferrari? Probably not. Would they like one if you offered it to them? Probably. Once they were used to driving around in a Ferrari, how easy do you think it would be to convince them to give it back? Nearly impossible. They would argue it is the only way to get to their appointments on time. Nothing else would measure up. So why would …

Reality Check | Is Your Current Customer Engagement Solution the Best Choice for All Markets? Read More »

4 principles for the future of pharma marketing

COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing? In this feature, Grünenthal’s Florent Eduoard and Kate Hurtig outline their principles for a new pharmaceutical marketing model.  “Keith, Kotler, Maslow” has long been the Holy Trinity of pharma marketing. Great ancient thinkers all aspiring marketeers were …

4 principles for the future of pharma marketing Read More »

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin franchise.  The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets …

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs Read More »

performance-io strikes multimillion-pound deal with STEM’s Rob Wood

Rob Wood has acquired a large minority stake in performance-io through a multimillion-pound deal that will see him join the specialist online performance marketing agency’s executive board. A former AstraZeneca director, Wood founded commercial and medical benchmarking firm STEM in 2007 before selling it to UDG Healthcare for £84 million in 2016. Since leaving that …

performance-io strikes multimillion-pound deal with STEM’s Rob Wood Read More »

Golin appoints Kat Arnull as UK strategy chief

Global comms agency Golin has appointed Kat Arnull as its first ever UK group chief strategy officer for Golin and Virgo Health. Kat starts her role with immediate effect, reporting into group managing director in London, Ondine Whittington, and working closely with Paul Parton, Golin’s global chief strategy officer. Arnull formally joins Golin after a …

Golin appoints Kat Arnull as UK strategy chief Read More »

Omnichannel customer-centric teams and the future of pharma CRM

If pharma companies are to live up to their decades-old patient-centric promises then marketing budgets need to move from brands and franchises to omnichannel customer-centric teams, according to one digital transformation leader. The industry is making some progress with this, but it’s not enough, says Edwin Erckens, who was until recently chief information officer within …

Omnichannel customer-centric teams and the future of pharma CRM Read More »

Branding Science opens new office in Germany

The healthcare brand consultancy Branding Science has opened a new office in Germany.  Founded 18 years ago, Branding Science has helped leading pharmaceutical and medical device companies with branding projects, from assessing market opportunity to preparing for upcoming launches and beyond. Dr Anne-Sophie Lenoir heads the new Berlin office. Born in Belgium, she has an …

Branding Science opens new office in Germany Read More »

Ketchum hires Neera Chaudhary as president of North America

Global communications consultancy Ketchum has announced the hire of Neera Chaudhary as president of North America.  Ketchum noted that Chaudhary has significant leadership experience at top public relations agencies and deep healthcare expertise across brands, corporate, nonprofits, government and public health organisations. Based in New York, she joined the firm this week and will be responsible for …

Ketchum hires Neera Chaudhary as president of North America Read More »

Veklury rescues Gilead from COVID doldrums in Q4

Gilead’s COVID-19 drug Veklury (remdesivir) is helping the company through disruption caused by the pandemic and patent expiry on two HIV drugs, according to its Q4 results announcement. In the final quarter alone, Veklury generated sales of just over $1.9 billion, offsetting a downturn in sales elsewhere in the business amid the disruption to healthcare …

Veklury rescues Gilead from COVID doldrums in Q4 Read More »

FDA holds back from action over Xeljanz safety study

The FDA has said it will wait for additional results from last week’s trial showing an increased risk of cardiac side effects with Pfizer’s arthritis blockbuster Xeljanz before deciding on further action. The post-marketing ORAL Surveillance safety study showed that JAK inhibitor Xeljanz (tofacitinib) was associated with a higher rate of heart attacks and cancer …

FDA holds back from action over Xeljanz safety study Read More »

3 Monkeys Zeno appoints Avril Lee to lead international role

3 Monkeys Zeno has appointed Avril Lee to the newly-created role of head of healthcare for the UK and Europe, as part of the UK agency’s plans to strengthen its international health capabilities. Lee joins 3MZ from The Red Consultancy, where she had been head of health since 2019, and was previously deputy chair of …

3 Monkeys Zeno appoints Avril Lee to lead international role Read More »

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 per share, consisting of $200 in cash and $20 in Jazz stock. That is a sizeable premium on GW’s closing share price of around $147 …

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma Read More »

Almirall names Nazzi as new CEO after Guenter leaves for Merck

Spanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to lead Merck KGaA’s healthcare unit earlier this month. Gianfranco Nazzi The new CEO is Gianfranco Nazzi, who will take over at Almirall on 1 May. For the last three years he has served as executive vice president, …

Almirall names Nazzi as new CEO after Guenter leaves for Merck Read More »

AstraZeneca on diversity: the pharmaphorum podcast

The theme for episode 28 of the pharmaphorum podcast is diversity and inclusion in pharma, ably addressed by AstraZeneca’s Rebekah Martin. Serving as senior vice president of reward and inclusion at AstraZeneca, Rebekah discussed how the pharmaceutical industry approaches the promotion of diversity. In an episode that was recorded in December 2020, she also talked …

AstraZeneca on diversity: the pharmaphorum podcast Read More »

COVID drives a customer experience shift in life sciences CRM

The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, according to new research from Gartner. Gartner’s’ CRM market guide notes that AI, digital scalability and hyper-automation hold the keys …

COVID drives a customer experience shift in life sciences CRM Read More »

COVID drives a customer experience shift in life sciences CRM

The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, according to new research from Gartner. Gartner’s’ CRM market guide notes that AI, digital scalability and hyper-automation hold the keys …

COVID drives a customer experience shift in life sciences CRM Read More »

Bad news for Pfizer as blockbuster Xeljanz flunks safety study

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety has achieved the opposite. The post-marketing safety study showed that Xeljanz (tofacitinib) – used to treat rheumatoid arthritis (RA) – was associated …

Bad news for Pfizer as blockbuster Xeljanz flunks safety study Read More »

Bad news for Pfizer as blockbuster Xeljanz flunks safety study

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety has achieved the opposite. The post-marketing safety study showed that Xeljanz (tofacitinib) – used to treat rheumatoid arthritis (RA) – was associated …

Bad news for Pfizer as blockbuster Xeljanz flunks safety study Read More »

Bedrock Healthcare Communications makes double hire

UK health comms agency Bedrock Healthcare Communications has announced that Chris Barton has joined as strategic solutions director, taking a place on the senior management team. He will work alongside strategic solutions director Meg Morgan, scientific solutions director Derek Annan, head of scientific services Catherine Lee and head of client services Emily Wigginton. In a …

Bedrock Healthcare Communications makes double hire Read More »

Bedrock Healthcare Communications makes double hire

UK health comms agency Bedrock Healthcare Communications has announced that Chris Barton has joined as strategic solutions director, taking a place on the senior management team. He will work alongside strategic solutions director Meg Morgan, scientific solutions director Derek Annan, head of scientific services Catherine Lee and head of client services Emily Wigginton. In a …

Bedrock Healthcare Communications makes double hire Read More »

Bomb scare sparks evacuation of plant making AZ COVID-19 vaccine

A plant in Wales manufacturing the AstraZeneca COVID-19 vaccine was evacuated on the advice of the authorities today after it was sent a suspicious package. Bomb disposal experts were called in to investigate the parcel at the fill and finish facility in Wrexham, operated by Wockhardt UK, which has the capacity to produce around 300 …

Bomb scare sparks evacuation of plant making AZ COVID-19 vaccine Read More »

What does the future hold for Medical Affairs?

“A new medical affairs communication model is emerging that provides greater collaboration and stakeholder engagement” I am a clinical pharmacist by training, but my interest lies in drug information. I found out about medical communications when working in the Drug Information Center at the Medical College of Virginia Hospitals. A colleague of mine offered to …

What does the future hold for Medical Affairs? Read More »

UK agency Aurora promotes Chris Bath to managing director

Independent UK comms agency Aurora has promoted Chris Bath to managing director. In a statement the London-based agency said Bath joined in 2015 and achieved rapid promotion to the agency’s management team. As well as providing senior counsel to clients and agency teams, he led the development of the agency’s digital insights capability and recently …

UK agency Aurora promotes Chris Bath to managing director Read More »

Plugging modular content into pharma’s omnichannel strategies

86% of respondents to a recent Veeva survey of pharma and biotech professionals said they are creating a greater volume of content now, compared to six months ago.  Yet while many pharma companies are creating more content than ever before, they also face increased pressure to quickly deliver highly personalised – and compliant – content …

Plugging modular content into pharma’s omnichannel strategies Read More »

ARK promotes King to client services director, hires Rodriguez as art director

London-based comms agency ARK has promoted Nicky King to client services director, with Martina Germinario Rodriguez joining as art director from Langland. King joined ARK, which describes itself as “the data-driven agency”, in 2018 as co-founder and account director and helped grow two of the biggest accounts in the group. After working with a variety …

ARK promotes King to client services director, hires Rodriguez as art director Read More »

Pharma digital transformation: customer data expected to play a pivotal role

A new survey highlights the importance of customer reference data to digital transformation and analyses ways pharma companies can improve the quality of their datasets. In a remote world, customer data is more foundational than ever, and Veeva’s 2020 European Customer Reference Data Survey found 91% of organisations view customer data as a global strategic …

Pharma digital transformation: customer data expected to play a pivotal role Read More »

GSK’s Neale Belson on building trust with employees and society

Pharma’s reputation is currently riding high as the industry comes together to tackle COVID-19, but GSK’s UK general manager Neale Belson says there is always more companies can do to build their culture and make sure employees and customers trust they are doing the right thing. When we spoke with Belson about the GSK’s response …

GSK’s Neale Belson on building trust with employees and society Read More »

Nine for 2021: Addressing the pandemic legacy

In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: the permanent changes in customer engagement models, the implications of a geographic re-balancing towards the East, CNS as the new value growth area for the 2020s, and the new biologics environment as biosimilars accelerate. …

Nine for 2021: Addressing the pandemic legacy Read More »

Tivicay approved in Europe in new dispersible tablet for children with HIV

ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by GlaxoSmithKline with Pfizer and Shionogi as shareholders, said the European Commission had granted a marketing authorisation for the new formulation. These tablets are used in combination with other antiretroviral agents …

Tivicay approved in Europe in new dispersible tablet for children with HIV Read More »

Amgen’s Enbrel heads ICER list of unjustified US price rises

US cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and concluded that seven of those were not backed by any clinical evidence. The cost to the American taxpayer from those increases? Around $1.2 billion for the seven drugs alone, says the organisation, which also found that for …

Amgen’s Enbrel heads ICER list of unjustified US price rises Read More »

Are face-to-face medical meetings a thing of the past?

Everything, from exercise classes to pub quizzes, went online last year – and medical education was no exception. In their droves, congresses, conferences, and masterclasses went virtual in a bid to ensure healthcare professionals were supported, up to date, and socially distanced. But is this change here to stay? Are the days of queuing for …

Are face-to-face medical meetings a thing of the past? Read More »

AmerisourceBergen buys Walgreens Boots Alliance wholesaling business for $6.5bn

US wholesale giant AmerisourceBergen is to buy the majority of Walgreens Boots Alliance’s wholesaling business for around $6.5 billion in a cash and shares deal. AmerisourceBergen will pay $6.275 billion in cash and around 2 million shares of its common stock for Alliance Healthcare in a deal to support its global distribution business. Alliance will …

AmerisourceBergen buys Walgreens Boots Alliance wholesaling business for $6.5bn Read More »

COVID-19 and the digital pharma marketing revolution

The global pandemic has caused pharma companies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Once the global emergency ends, this trend will continue, argues pharmaphorum’s Richard Staines. The global outbreak of COVID-19 has forced businesses to radically change their way of working. Healthcare companies have been …

COVID-19 and the digital pharma marketing revolution Read More »

Health strategy consultancy CREATION.co makes two senior hires

Health strategy consultancy CREATION.co has made two senior appointments, with former government analyst Tom Bourne and former TV marketer Victoria Donougher getting on board. Bourne has joined as associate director, analytics overseeing a team of 36 analysts, data scientists and language specialists at the company’s global offices. His brief will be to lead the team …

Health strategy consultancy CREATION.co makes two senior hires Read More »

Pfizer drops the blue pill, kicks off 2021 with new DNA logo

Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. The logo – which retains the company’s traditional blue colour scheme – has been more …

Pfizer drops the blue pill, kicks off 2021 with new DNA logo Read More »

Ex-Resolute co-founder Blackburn starts hybrid agency Certain Health

Former joint founder and owner of Resolute Communications and Real Science Paul Blackburn has launched a new hybrid agency, Certain Health. Blackburn made the move after Resolute and Real Science were absorbed into Publicis Langland. The company said its hybrid model has the benefits of both the traditional and virtual agency models, with expertise in …

Ex-Resolute co-founder Blackburn starts hybrid agency Certain Health Read More »

UK parliament backs EU trade deal, as industry sifts through detail

The post-Brexit trade deal agreed on Christmas Eve has been overwhelmingly backed by the UK parliament, providing some degree of stability – but also plenty of disruption – for the coming months and years. The UK is leaving the EU’s single market and customs union, but the deal means tariffs on goods won’t be imposed …

UK parliament backs EU trade deal, as industry sifts through detail Read More »

The top 5 pharma M&A deals of 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. That said, there were still some interesting moves indicating new directions of travel for big pharma players – with most …

The top 5 pharma M&A deals of 2020 Read More »

Have you checked your brand’s temperature?

In today’s fast-paced world how do you make sure your brand messages resonate with your customers and, if they do, how can your brand become even more remarkable? These questions have always been relevant for healthcare communications, but the new world in which we all find ourselves have made them particularly pertinent as our customers’ …

Have you checked your brand’s temperature? Read More »

Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the table

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and-stock takeover offer. The deal – the largest in the pharma sector since the start of the pandemic – bolsters AZ’s immunology franchise …

Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the table Read More »

Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the table

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and-stock takeover offer. The deal – the largest in the pharma sector since the start of the pandemic – bolsters AZ’s immunology franchise …

Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the table Read More »

OVID Health appoints high-profile leaders as senior counsel

Independent communications agency OVID Health has appointed Niall Dickson, professor David Salisbury and Athena Lamnisos as senior counsel, providing strategic advice and thought leadership across several projects involving healthcare and pharma clients. In addition to these appointments, Grace Holland has joined the team as account manager. For more than thirty years Niall Dickson has been …

OVID Health appoints high-profile leaders as senior counsel Read More »

UK, EU agree Northern Ireland medicines, food border controls

The UK and EU have reached an agreement on border checks for Northern Ireland that should guarantee that trade in medicines and food continues without disruption after 1 January – regardless of whether eleventh-hour negotiations result in a trade deal. The agreement means that the UK government will not press ahead with plans to override …

UK, EU agree Northern Ireland medicines, food border controls Read More »

Are pharma’s TV ad strategies out of date?

TV viewing habits are changing dramatically, and these trends have only been accelerated by COVID-19 – but Intouch’s Justin Chase says that pharma is still stuck in a traditional advertising mindset. Drawing on research from a recent whitepaper, he tells us how the industry can optimize its TV advertising for an age of hyper-targeted media …

Are pharma’s TV ad strategies out of date? Read More »

A history of Pfizer

Few companies embody the term ‘pharma giant’ as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent German immigrants to the USA, Charles Pfizer and Charles Erhart. Both in their mid-twenties, the two men set …

A history of Pfizer Read More »

Online Live Team Pharma Forecasting Training Now Available

Working remotely can have its challenges, why not get together for a fun and rewarding learning experience and refresh your forecasting skills? Following the success of J+D Forecasting’s face to face training, the content has been redesigned to make it suitable for live, online audiences.  There are two types of courses, type one is tailored …

Online Live Team Pharma Forecasting Training Now Available Read More »

Langland appoints Angela Rochelle to clinical trial diversity role

Langland has announced the appointment of Angela Rochelle as account director, head of diversity initiatives in clinical trials. Rochelle will be the agency’s leading advocate for diversifying patient representation in Clinical Trial Experience (CTE). She will collaborate with Langland’s established clinical trial inclusivity taskforce—a team committed to designing and deploying clinical trial communications that proactively …

Langland appoints Angela Rochelle to clinical trial diversity role Read More »

VMLY&R creates global healthcare agency for innovative pharma companies

Marketing agency VMLY&R has launched a new global healthcare agency, VMLY&Rx, to service specialty prescription pharmaceutical companies developing innovative breakthrough therapies. The global VMLY&Rx offering has been created by aligning teams from within WPP Health Practice — including the specialist talent from Sudler in France, UK, Germany, Italy, Switzerland, Spain, China, and Japan — with …

VMLY&R creates global healthcare agency for innovative pharma companies Read More »

The calm after the storm: How COVID-19 is making pharma more resilient

COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning how to overcome the challenges of 2020 will serve the industry well for years to come. As part of our EU Leader series, Christian Pawlu, head of strategy, portfolio and BD&L at Sandoz, told us about how …

The calm after the storm: How COVID-19 is making pharma more resilient Read More »

Alliance and Boots donate dexamethasone to NHS

The UK’s largest medical wholesaler and pharmacy have donated half a million dexamethasone tablets to support the effort against COVID-19. Alliance Healthcare and Boots, both part of Walgreens Boots Alliance, donated the 2mg Almus Dexamethasone tablets to the NHS to support it during the pandemic. The decision followed the findings of the RECOVERY trial, which …

Alliance and Boots donate dexamethasone to NHS Read More »

Russian Sputnik COVID-19 vaccine ‘will cost less than $10 a dose’

The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. Sputnik V’s efficacy has remained high at 91.4% according to the latest analysis, which comes from …

Russian Sputnik COVID-19 vaccine ‘will cost less than $10 a dose’ Read More »

FDA approves Roche’s Xofluza to prevent flu spreading in families

The FDA has approved a new use for Xofluza (baloxavir marboxil) from Roche’s Genentech unit, to prevent people developing flu after coming into contact with an infectious person. Xofluza has already been on the market for two years, and already had licensed uses to treat uncomplicated flu and those at high risk of complications. With …

FDA approves Roche’s Xofluza to prevent flu spreading in families Read More »

Media means business

COVID-19 has left us more reliant on media than ever – both the pharma industry and society as a whole. Havas Lynx Group’s 2020 white paper provides a blueprint for pharma brands to inject meaning into their media. “Meaningful media experiences are made by connecting with the right people, in the contexts they spend their …

Media means business Read More »

Prescient Announces Recent Appointments to its Senior Team

Prescient hires three new senior members to expand its expertise and keep pace with the company’s growth LONDON, November 3, 2020 – Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members: Gordon Gochenauer, Dr. Priya Kar and Dr. Cameron Mackenzie. They join the existing leadership team, which …

Prescient Announces Recent Appointments to its Senior Team Read More »

GCI London bolsters leadership with David Berkovitch hire

GCI Health’s London office has bolstered its senior leadership team with the hire of David Berkovitch, who joins after a four-year stint at 3 Monkeys Zeno and previous roles at Edelman and Fleishman Hillard Fishburn. Kath Kerry, MD at GCI Health commented, “We are thrilled to have Dave join the GCI Health family. He and …

GCI London bolsters leadership with David Berkovitch hire Read More »

Pharma needs to adapt its communications or be left behind

As the world continues to grapple with the ongoing impact of coronavirus, the healthcare industry has taken centre-stage, working tirelessly and more collaboratively than ever to tackle challenges thrown up by the pandemic. Amid the turmoil and the race to not only find a vaccine but also help to care for those who are battling …

Pharma needs to adapt its communications or be left behind Read More »

Envision acquires commercial solutions firm Two Labs

Scientific communications company Envision Pharma has bought Two Labs, a firm specialising in commercial solutions for the pharma and biotech sector, for an undisclosed sum. The combined company will bring together complementary clients, services, and technologies, extending Envision’s scientific footprint to new clients in the “product pre-launch setting” – while opening up new business avenues …

Envision acquires commercial solutions firm Two Labs Read More »

Fresh doubts over BMS’ merger payout as FDA delays key drug review

Holders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out after the company said COVID-19 travel restrictions are delaying a key regulatory review. Shareholders in Celgene received a contingent value right (CVR) at the time of the company’s $74 billion merger with BMS last year, which pay …

Fresh doubts over BMS’ merger payout as FDA delays key drug review Read More »

Divided Congress paves way for drug price reforms on Biden’s watch

Unless president Donald Trump is successful with legal challenges, Democratic rival Joe Biden looks to have won the White House in last week’s election but faces the challenges of a divided Congress when it comes to implementing important health policies. Making healthcare affordable is one of Biden’s goals as many Americans struggle to pay for …

Divided Congress paves way for drug price reforms on Biden’s watch Read More »

Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?

Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor fears that a payout tied new product approvals was in jeopardy. BMS’ stock fell a little over 2%, but the big casualty was a contingent value right (CVR) due to former shareholders in Celgene, which BMS acquired …

Could an FDA inspection scupper CVR deadline for BMS’ liso-cel? Read More »

Lundbeck tops Q3 expectations following strong sales of mental health drugs

Denmark’s Lundbeck has beat its expectations in third quarter results, following a strong performance from its portfolio of mental health drugs, although its newly-launched migraine drug seems to have got off to a slow start. Lundbeck posted quarterly sales of 4.46 billion Danish kroner ($693.39 million), which Reuters noted beat expectations of around 4.39 billion …

Lundbeck tops Q3 expectations following strong sales of mental health drugs Read More »

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products. The Federal Trade Commission (FTC) has ruled that the combined company – to be called Viatris – could have an anticompetitive position in the US market for …

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions Read More »

Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply deal

Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 billion in deposits for the shot. The figure was revealed by CEO Stéphane Bancel in Moderna’s third-quarter results call on which he also highlighted a new agreement to supply …

Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply deal Read More »

Gilead Q3 revenue rise bolstered by $873m Veklury sales

Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment with its Veklury antiviral, and its latest financial results reveal the benefit of that achievement. The US drugmaker sold $873 million-worth of Veklury (remdesivir) in the three months to the end of September, helping it to a …

Gilead Q3 revenue rise bolstered by $873m Veklury sales Read More »

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end of earnings guidance for the year. The bounce-back wasn’t enough to ease investor worries however – with fresh lockdowns …

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares Read More »

10 Tips for Digital Asset Management Success

Given the recent rise in digital engagement and the drastic increase in digital content, it’s now essential that pharmaceutical companies have a comprehensive content strategy. A foundational step in this process is to implement an integrated solution for digital asset management (DAM) and medical, legal and regulatory (MLR) review. This enables pharma companies to simplify …

10 Tips for Digital Asset Management Success Read More »

Purdue to pay $8.3bn after admitting criminal charges in opioid case

After years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in the US opioid epidemic that will cost it up to $8.3 billion. As part of the criminal and civil settlement, the manufacturer of opioid painkiller OxyContin (oxycodone) pleaded guilty to a three-count felony, including two counts of …

Purdue to pay $8.3bn after admitting criminal charges in opioid case Read More »

Time to change the channel? The future for customer engagement models

Sarah Rickwood delves into IQVIA data to find out exactly how pharma’s HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic. The pandemic has triggered a change in how pharmaceutical companies are engaging with healthcare professionals. With in-person visits drastically reduced, pharma has been challenged to find …

Time to change the channel? The future for customer engagement models Read More »

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

Combination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies. The combination therapies had previously been marketed following accelerated approval in November 2018 on the basis of early stage results. But accelerated approval is only a temporary measure and …

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies Read More »

COVID-19 tests prop up Roche as US biosimilars bite in Q3

Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike in demand for COVID-19 tests spared the Swiss company’s blushes. Sales of its “big three” cancer drugs were all down considerably in Q3 as cheaper biosimilars gained market share in the US. Avastin was down 30% compared …

COVID-19 tests prop up Roche as US biosimilars bite in Q3 Read More »

Accelerating the digital approval process

The boom in digital tech over COVID means that pharma can move faster than ever – but the industry’s traditional processes for asset approval are still holding timelines back. David Reily examines how pharma companies are responding to the increased burden of asset approval with new ways of working. The coronavirus pandemic has forced a …

Accelerating the digital approval process Read More »

Harmony’s sleep disorder drug Wakix gets US label extension

Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom of the sleep disorder that can cause total body collapse. Wakix (pitolisant) was first approved in August 2019 for treatment of excessive sleepiness in adults with narcolepsy. It is the only FDA-approved drug to treat cataplexy associated …

Harmony’s sleep disorder drug Wakix gets US label extension Read More »

Pharma’s response to COVID: GSK

A few months into the pandemic, the world is now moving beyond managing the crisis, with more focus on addressing the collateral damages and shaping the future. As part of a new series looking at how pharma has responded to the pandemic, Neale Belson, SVP UK & Ireland and general manager for the UK at …

Pharma’s response to COVID: GSK Read More »

Pharma’s digital transformation journey and the role of customer reference data

Better management of customer data could help pharmaceutical companies’ digital transformation, according to Veeva’s Rebecca Silver. pharmaphorum’s Richard Staines spoke to her about how the use of customer reference data can transform pharma companies, increase competitiveness, and benefit the bottom line during these challenging times. Precision medicine is emerging as a key approach for disease …

Pharma’s digital transformation journey and the role of customer reference data Read More »

J&J settles 1,000 talc lawsuits for $100m+; report

Johnson & Johnson has agreed to pay more than $100 million to settle over 1,000 lawsuits that allege the company’s Baby Powder talc products caused cancer, according to Bloomberg. Citing people close to the matter, the news agency said the settlement marks the first time that J&J has opted to settle litigation in bulk, rather …

J&J settles 1,000 talc lawsuits for $100m+; report Read More »

W2O acquires health policy consulting firm Discern Health

W2O has bought US health economics and outcomes research company Discern Health, marking its sixth acquisition in less than a year. The move will give Discern Health access to healthcare communications agency W2O’s proprietary data models and tools, as well as its 1,400-person-strong multidisciplinary team – including data analysts, scientific strategists, branding experts, communications specialists …

W2O acquires health policy consulting firm Discern Health Read More »

Teva charged in US price-fixing investigation

The US Department of Justice has charged Teva with conspiring with other pharma companies to fix prices for generic drugs. According to an indictment filed on Tuesday, the company participated in three counts of conspiracy from at least May 2013 until around December 2015, which could have resulted in customers being overcharged by at least …

Teva charged in US price-fixing investigation Read More »

Behind the scenes of the new ABPI Code of Practice

For over 60 years the ABPI Code of Practice has been key to the UK industry’s self-regulation, and now, as pharma is experiencing its most intense period of change in decades, a new update seeks to bring the Code in line with the modern sector. With the new Code now in its consultation stage, we …

Behind the scenes of the new ABPI Code of Practice Read More »

Takeda agrees $2.3bn sale of Japanese consumer health unit

Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs. The drugmaker is divesting Takeda Consumer Healthcare, which operates mainly in Japan, to private equity group Blackstone for 242 billion yen ($2.3 billion), with the deal expected to close in March of next year. …

Takeda agrees $2.3bn sale of Japanese consumer health unit Read More »

Merck makes communications leadership change

German pharmaceutical company Merck has appointed Thomas Möller as its new head of group communications. Most recently responsible for corporate communications, Möller has worked at Merck since 2017, when he joined as head of external communications. Prior to that he served as head of media relations at BASF and held various corporate communications positions in …

Merck makes communications leadership change Read More »

UK doctors call for tighter rules on coronavirus antibody tests

Doctors have called for rules to be tightened on coronavirus antibody tests in the UK amid fears that false readings could put the public at risk. It’s not even known for sure that having antibodies against the SARS-CoV-2 coronavirus confers immunity. But with many other diseases the presence of specific antibodies indicates that the body …

UK doctors call for tighter rules on coronavirus antibody tests Read More »

Creative agency woolley pau regains independence after buyout

Healthcare marketing agency woolley pau has gone back to its independent roots following a management buyout by three of its senior team. Ed Shorthose, managing director, said the move “felt right on every level”. Shorthose, Christian Dawson and Dean Woolley bought out the agency, which was had previously been acquired by healthcare communications company gyro …

Creative agency woolley pau regains independence after buyout Read More »

Teva shares slide as it faces illegal kickback charges from US government

Shares in Teva were down sharply this week after the US Department of Justice filed a complaint that the company paid illegal kickbacks to patient groups to boost sales of its multiple sclerosis drug Copaxone (glatiramer). The allegation is that Teva’s subsidiaries Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. illegally paid Medicare co-payment costs …

Teva shares slide as it faces illegal kickback charges from US government Read More »

Regeneron recruits Roche to make COVID-19 antibody drug REGN-COV2

Roche has agreed to help Regeneron manufacture its COVID-19 antibody cocktail REGN-COV2, which started late-stage clinical testing a few weeks ago, in a deal that could more than triple supplies of the drug if it gets approved. Regeneron is already working on ramping up manufacturing capacity for REGN-COV2, with the help of $450 million in …

Regeneron recruits Roche to make COVID-19 antibody drug REGN-COV2 Read More »

Pharma improves HCP engagement during COVID-19 – report

Pharma companies have improved how they engage with healthcare providers as a result of COVID-19, according to a new survey of HCPs. This has resulted in pharma companies being more relevant and providing more value in closing the care gap, the report says. The Accenture survey of 720 general practitioners, oncologists, cardiologists and immunologists globally …

Pharma improves HCP engagement during COVID-19 – report Read More »

Roche takes on Alexion as FDA approves satralizumab in NMOSD

The FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the brand name Enspryng. Roche is taking on Alexion’s blockbuster Soliris (eculizumab), which was approved in NMOSD last year and in June Viela Bio, a spinoff from AstraZeneca, also won approval for another rival, Uplinza (inebilizumab). The big …

Roche takes on Alexion as FDA approves satralizumab in NMOSD Read More »

Cello Health acquired for £182m by private equity firm

Cello Health has been acquired by Arsenal Capital Partners, a private equity firm investing in healthcare and industrials companies. Arsenal said the £181.8 million deal would give it the foundation for a new enterprise to enable its healthcare and biopharmaceutical clients to maximise the value of their products. Jon Williams, CEO of Arsenal’s new planned …

Cello Health acquired for £182m by private equity firm Read More »

What can pharma marketing learn from other regulated industries?

The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers. No one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social …

What can pharma marketing learn from other regulated industries? Read More »

EU places firm order for AZ/Oxford Uni’s ChAdOx1 COVID-19 vaccine

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. ChAdOx1 – which is in large-scale phase 2/3 trials – was licensed by AZ in April and renamed AZD1222, and …

EU places firm order for AZ/Oxford Uni’s ChAdOx1 COVID-19 vaccine Read More »

Emotional empathy is driving brand equity

How the COVID-19 pandemic is forging pharmaceutical brands into better shape. Day by day it becomes clearer that some brands are coming through the pandemic in better shape than ever.  These are the brands that have clearly demonstrated emotional intelligence, that have shown emotional empathy to their target audience. They understand the current, heightened emotional …

Emotional empathy is driving brand equity Read More »

Anger at US deal for Moderna’s ‘taxpayer-funded’ COVID-19 vaccine

The US government has signed another big coronavirus vaccine supply deal, snapping up 100 million doses of Moderna’s mRNA jab for a little over $1.5 billion –around $15 per dose or $30 per course. That’s a steep discount on the $32 to $37 price per dose in its earlier smaller deals, revealing that purchasing power …

Anger at US deal for Moderna’s ‘taxpayer-funded’ COVID-19 vaccine Read More »

Intouch Group hires Susan Perlbachs as chief creative officer

Intouch Group has announced the hire of Susan Perlbachs as its chief creative officer (CCO). As CCO, Perlbachs will be responsible for creative leadership across all Intouch Group affiliates, locations and clients. She will be based in Intouch’s New York office. “I’m looking forward to being part of this award-winning organisation that I’ve admired for quite some time,” said Perlbachs. “I’m …

Intouch Group hires Susan Perlbachs as chief creative officer Read More »

Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes

In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Though Novo Nordisk is perhaps not as much of a household name as other pharma companies in the UK, it …

Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes Read More »

Bad behaviour: why understanding human behaviour can improve outcomes

Why did I do that? A common question I often ask myself after opening the biscuit packet for the third time in an hour. Only ten minutes before I had a mental argument with myself, which I thought I had won, promising not to eat another one until tomorrow. The process that goes on inside …

Bad behaviour: why understanding human behaviour can improve outcomes Read More »

Pharma’s rep soars on back of COVID-19, says FutureBrand

The perception of pharma and medical product companies has surged forward since the start of the COVID-19 pandemic, but they still lie mostly outside the top-rated firms in the FutureBrand Index. Roche, AstraZeneca, Novo Nordisk, and Sanofi all shot up the rankings in the first edition of the report since the start of the coronavirus …

Pharma’s rep soars on back of COVID-19, says FutureBrand Read More »

Bayer slides on €9.5bn loss caused by litigation, COVID-19 impact

Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion net loss made worse by lower sales in its pharma and consumer health divisions. Group sales were down 2.5% to just over €10 billion, with pharma falling 8.8% to just under €4 billion, “weighed down” by COVID-19 …

Bayer slides on €9.5bn loss caused by litigation, COVID-19 impact Read More »

Preparing for an influx of cell and gene therapy approvals

Cell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has ever seen. However, to fully realise the potential of these innovative therapies, integration across the supply chain is critical – particularly with reimbursement and logistics. As of the end of 2019, there were 17 cell and gene …

Preparing for an influx of cell and gene therapy approvals Read More »

Novartis, company culture and COVID-19: the pharmaphorum podcast

Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face of company culture, now and in the future. We also looked at how Novartis’ own operations had to change in response to the coronavirus pandemic and the considerable challenges that presented him as its chief people and …

Novartis, company culture and COVID-19: the pharmaphorum podcast Read More »

Next wave: how pharma analytics can be improved with new technologies

Pharmaceutical companies have always had access to a steady stream of data to look at what has happened in the past and to try to predict future prescribing trends. Business intelligence (BI) departments have supported this throughout with timely and effective reporting, within an environment that has seen in recent years a bit of an …

Next wave: how pharma analytics can be improved with new technologies Read More »

After final $600M opioid settlement, Indivior looks to the future

UK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in the US behind it, after agreeing a $600 million settlement. The deal resolves criminal and civil liabilities faced by the company related to charges it engaged in an illicit nationwide scheme to increase prescriptions of opioid addiction …

After final $600M opioid settlement, Indivior looks to the future Read More »

Country focus: Iraq’s pharma industry sees upward trajectory

After decades of turmoil, Iraq’s healthcare sector is growing fast – but the country still holds some unique challenges for companies looking to enter its market. We spoke to Ali Mosawi, founder of Al Hayat Scientific Office, to get his view on the past, present and future of healthcare in Iraq, and find out what …

Country focus: Iraq’s pharma industry sees upward trajectory Read More »

BCW promotes Catherine Keddie and Tamsin Tierney

BCW (Burson Cohn & Wolfe) has bolstered its healthcare leadership team, promoting Catherine Keddie and Tamsin Tierney to new roles. Keddie (pictured above left) becomes group managing director for healthcare and head of culture, UK at the healthcare communications agency, with responsibility for overseeing the continued growth of BCW’s UK Healthcare business. She’s been with …

BCW promotes Catherine Keddie and Tamsin Tierney Read More »

UK pharma resilient in 2Q, despite pandemic fallout

UK manufacturing exports fell sharply during the second quarter as the COVID-19 pandemic gathered pace, but pharma and healthcare products were much less affected, says a Lloyds Bank report. The latest quarterly UK International Trade Index reveals that the Chemicals and Plastics sector – which covers pharma and healthcare – was particularly resilient in the …

UK pharma resilient in 2Q, despite pandemic fallout Read More »

How modular content provides ‘light-speed’ review and boosts engagement

Twenty-first century communications are fast, personalised and multi-channel – all of which can seem diametrically opposed to the heavily-regulated world of the pharmaceutical industry. But an innovative, modular approach to content creation can facilitate rapid updates and enhance customer engagement across channels. The COVID-19 pandemic has hugely altered healthcare professionals’ (HCP) behaviour. They are seeing …

How modular content provides ‘light-speed’ review and boosts engagement Read More »

MSD’s David Peacock on moving UK healthcare forward

David Peacock has worked across the world for MSD and other companies, and has now taken the helm of MSD’s UK & Ireland operations. In the latest article in our UK Leaders series, he tells us about the opportunities and challenges he is excited to take on in the region. Peacock has had a strikingly …

MSD’s David Peacock on moving UK healthcare forward Read More »

Healthware launches global resource hub for COVID-19’s ‘new normal’

Healthware has launched a new online resource that aggregates information and analysis on how to respond to the huge changes COVID-19 has wrought across life sciences and healthcare. The open access newnormal.health aims to help guide executives from pharma, biotech and medical device companies in their response to the pandemic and its aftermath. Roberto Ascione, …

Healthware launches global resource hub for COVID-19’s ‘new normal’ Read More »

Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst

JP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high even if its COVID-19 vaccine mRNA-1273 succeeds in clinical trials. Moderna’s share price has rocketed 385% this year, driven by the development of mRNA-1273, but the analysts think there are too many unknowns surrounding the coronavirus pandemic …

Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst Read More »

The enduring innovation and behaviour changes from COVID-19

The COVID-19 crisis has accelerated the shift to a more resilient, agile and innovative digitally-enabled world within healthcare and pharma. But the best companies are going further – by enhancing and expanding their digital channels they are using this as an opportunity for enduring change. Continuing our series on digital health and COVID-19, David Reilly …

The enduring innovation and behaviour changes from COVID-19 Read More »

Jo Spadaccino joins healthcare comms agency ZPB as a partner

PR agency ZPB has appointed Jo Spadaccino as a partner to help realise its ambition of offering an integrated market strategy for the pharma, healthcare services and tech sectors. She joins the London-based healthcare communications agency from Pegasus, where she spent 10 years, most recently leading an 85-strong team as head of client partnerships. Spadaccino …

Jo Spadaccino joins healthcare comms agency ZPB as a partner Read More »

Alnylam’s Anant Murthy on making it as a US biotech in Europe

Alnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how a US biotech can adapt to the many unique challenges of the EU market. Though they represent the two biggest markets for pharma companies, the EU and US have some stark differences that can often catch out …

Alnylam’s Anant Murthy on making it as a US biotech in Europe Read More »

Urgent vacancy at Mankind

Urgent vacancy at Mankind *Vacancy*of Medical Representative in *Mankind Pharma Ltd*Div-Future (cardiometabolic ) At *HQ- BHOPAL* Qualification-Graduate/D.PharmaExperienced person will be preferred (6month to 1year Experienced & Age limit -27Years)Contact-Durgesh JaiswalMob.No – *9993498485* Visit above links for more information

Urgent vacancy at Usv ltd

Urgent vacancy at Usv ltd *Vacancy for the Post of MR* *USV* Private Limited *HQ* –  Nagpur Minimum 6 Month Experience. Qualification:- BSc, B Pharm, D Pharm. Interested Candidate Can Call and can Send Resume on following mail id. Vipin RamtekeArea Manager.9673972240.Email id– vipinramteke2007@gmail.com Visit above links for more information

Urgent vacancy at Centaur

Urgent vacancy at Centaur Dear all,We require candidate for Opthalmic Division *(Praggya)* of *”CENTAUR Pharmaceuticals Pvt Ltd* at Bhopal HQ.Please suggest Good Candidates for the Post of Medical Representative,Should Be from Science Background,Fresher should also apply. Age not more then 28 years Call-Mr MANISH KANUNGO (ASM)9827337635Email-manishkanungo04@gmail.com Visit above links for more information

Urgent vacancy at Ipca

Urgent vacancy at Ipca Vacancy For Medical Represtative in Ipca Labs Ltd.Div. Intima (Product :Lariago ,Lumerax,Pacimol)HQ.IndoreEligibility CriteriaAge Max 27Qualification: Graduate ,Science And Pharmacy Candidate Will  be Preferd .Minimum 6 Month Experience is Must .ContactS K MishraABMIndoreMob No. 9589171245 Visit above links for more information

Urgent vacancy at Alkem

Urgent vacancy at Alkem *Alkem Laboratories Ltd**Division – Alpha Max* Required a Medical Representative*H.Q. – Dhar* Experience required min – 6 month Contact –Rakesh ChejaraArea Business ManagerMob – 8109229335Mail I’d – rakesh.chejara@alkem.com Visit above links for more information

Urgent vacancy at Walter Bushnell

Urgent vacancy at Walter Bushnell Dear friends,We have  Vacancies  for M.R *Walter Bushnell Pvt Ltd*Brand – *Drotin ,urispas* Area :Kem hospitalCharni roadLower parelColaba Qualifications – D pharma , B pharma and Bcom Package: Negotiable Experience 12 month Please contact(ASM) Amit Singh   9323668102(ASM) Kailash Mahajan 9920317922(RSM) Somnath sir72081 71134 Visit above links for more information

Urgent vacancy at Zenerax health care.

Urgent vacancy at Zenrex health care. ZENRAX HEALTH CARERequired Medical ExecutiveFor:-OLD BHOPAL HQExperience candidate Contact personRAVINDRA SINGHCONTACT 9329980434ravindradhakar@zenrax.com Visit above links for more information

Urgent vacancy at Zydus health care.

Urgent vacancy at Zydus health care. Executives Required💼Company : Zydus Healthcare Ltd🎨Division : CARDIVAHQ:  Chennai VELACHERY💺Designation: BO Business  officer⌛Experience:Minimum 6 Months Experience👨🏻‍🎓Degree: Any Degree👉🏼Contact: SOUNDAR RAJAN📞Mobile.- 7358792205📧 Mail – zydcnd.soundarrajan@gmail.com Visit above links for more information

Urgent vacancy at FDC Ltd.

Urgent vacancy at FDC Ltd. *Urgently Requirement*Medical representative.Post: TMCompany :-FDC PVT LTDHQ : IndoreDivision- ProximaQualification : Science GraduateExp-1 years with good communication  also  applyNOTE- *Age should not be more than 28 YearsInterested Candidatecan send their resumes at -pariharlok9595@gmail.comMob. 8770968055 Visit above links for more information